{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:00:10Z","timestamp":1793350810296,"version":"4.5.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the National Key Research and Development Program of China","award":["2022YFC2305800"],"award-info":[{"award-number":["2022YFC2305800"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82341042"],"award-info":[{"award-number":["82341042"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["22007105"],"award-info":[{"award-number":["22007105"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Nasal vaccines offer advantages in eliciting mucosal immunity, particularly through the induction of dimeric IgA. However, the complex mucosal environment poses challenges in achieving optimal immunogenicity and safety. This study introduced Diprovocim, a TLR2 agonist, as an effective and safe adjuvant for mucosal vaccines. Our results demonstrated that Diprovocim self-assembled into particles of suitable size for mucosal delivery, enhancing antigen phagocytosis of immune cells in both lymph nodes and lungs. After effectively activating the TLR2 signaling pathway, Diprovocim led to a reduced release of inflammatory cytokines in vivo without any tissue damage or weight loss, highlighting its safety profile. In mice, both intramuscular and intranasal immunization with Diprovocim-adjuvanted vaccines induced high titers of systemic antibodies. Higher IgG and IgA antibodies were detected in bronchoalveolar lavage fluid (BALF). Moreover, Diprovocim enhanced the immunogenicity of ovalbumin (OVA) and recombinant SARS-CoV-2 protein (RFD-Fc) vaccines, achieving higher CD4\n                    <jats:sup>+<\/jats:sup>\n                    and CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cell immune responses and cross-protection against SARS-CoV-2 variants. These findings highlight the potential of self-assembled Diprovocim as a safe and effective adjuvant for mucosal vaccines, offering a promising strategy for combating respiratory infections.\n                  <\/jats:p>","DOI":"10.1038\/s41541-025-01185-y","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T12:00:36Z","timestamp":1750248036000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Self-assembling TLR2 agonists promote mucosal immune responses without pulmonary immunopathologic injuries in mice"],"prefix":"10.1038","volume":"10","author":[{"given":"Zhangping","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiguanxi","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liru","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiafeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"key":"1185_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-020-02995-9","volume":"11","author":"S Platto","year":"2020","unstructured":"Platto, S., Xue, T. & Carafoli, E. COVID19: an announced pandemic. Cell Death Dis. 11, 1\u201313 (2020).","journal-title":"Cell Death Dis."},{"key":"1185_CR2","first-page":"147","volume":"21","author":"O Puhach","year":"2023","unstructured":"Puhach, O., Meyer, B. & Eckerle, I. SARS-CoV-2 viral load and shedding kinetics. Nat. Rev. Microbiol. 21, 147\u2013161 (2023).","journal-title":"Nat. Rev. Microbiol."},{"key":"1185_CR3","unstructured":"The top 10 causes of death. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death."},{"key":"1185_CR4","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.3390\/vaccines9121499","volume":"9","author":"M Guerrieri","year":"2021","unstructured":"Guerrieri, M. et al. Nasal and salivary mucosal humoral immune response elicited by mRNA BNT162b2 COVID-19 vaccine compared to SARS-CoV-2 natural infection. Vaccines 9, 1499 (2021).","journal-title":"Vaccines"},{"key":"1185_CR5","doi-asserted-by":"publisher","first-page":"eabn1413","DOI":"10.1126\/scitranslmed.abn1413","volume":"14","author":"BL Hartwell","year":"2022","unstructured":"Hartwell, B. L. et al. Intranasal vaccination with lipid-conjugated immunogens promotes antigen transmucosal uptake to drive mucosal and systemic immunity. Sci. Transl. Med. 14, eabn1413 (2022).","journal-title":"Sci. Transl. Med."},{"key":"1185_CR6","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1172\/JCI135020","volume":"130","author":"A Lin","year":"2020","unstructured":"Lin, A. et al. Live attenuated pertussis vaccine BPZE1 induces a broad antibody response in humans. J. Clin. Investig. 130, 2332\u20132346 (2020).","journal-title":"J. Clin. Investig."},{"key":"1185_CR7","doi-asserted-by":"publisher","first-page":"eabf5314","DOI":"10.1126\/sciimmunol.abf5314","volume":"7","author":"H-X Tan","year":"2022","unstructured":"Tan, H.-X. et al. Lung-resident memory B cells established after pulmonary influenza infection display distinct transcriptional and phenotypic profiles. Sci. Immunol. 7, eabf5314 (2022).","journal-title":"Sci. Immunol."},{"key":"1185_CR8","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41385-021-00461-z","volume":"15","author":"MZM Zheng","year":"2022","unstructured":"Zheng, M. Z. M. & Wakim, L. M. Tissue resident memory T cells in the respiratory tract. Mucosal Immunol. 15, 379\u2013388 (2022).","journal-title":"Mucosal Immunol."},{"key":"1185_CR9","doi-asserted-by":"crossref","unstructured":"Kumar Bharathkar, S. et al. The structures of secretory and dimeric immunoglobulin A. eLife 9, e56098 (2020).","DOI":"10.7554\/eLife.56098"},{"key":"1185_CR10","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.cell.2020.08.026","volume":"183","author":"AO Hassan","year":"2020","unstructured":"Hassan, A. O. et al. A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2. Cell 183, 169\u2013184.e13 (2020).","journal-title":"Cell"},{"key":"1185_CR11","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1086\/423001","volume":"39","author":"RB Belshe","year":"2004","unstructured":"Belshe, R. B. et al. Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years. Clin. Infect. Dis.39, 920\u2013927 (2004).","journal-title":"Clin. Infect. Dis."},{"key":"1185_CR12","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s40264-017-0605-3","volume":"41","author":"PV Nigwekar","year":"2018","unstructured":"Nigwekar, P. V. et al. Safety of Russian-Backbone Trivalent, live attenuated seasonal influenza vaccine in healthy subjects: open-label, non-randomized phase 4 study. Drug Saf. 41, 171\u2013177 (2018).","journal-title":"Drug Saf."},{"key":"1185_CR13","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S0140-6736(21)02753-7","volume":"399","author":"SA Halperin","year":"2022","unstructured":"Halperin, S. A. et al. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial. Lancet Lond. Engl. 399, 237\u2013248 (2022).","journal-title":"Lancet Lond. Engl."},{"key":"1185_CR14","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.addr.2004.09.004","volume":"57","author":"H Alpar","year":"2005","unstructured":"Alpar, H., Somavarapu, S., Atuah, K. & Bramwell, V. Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv. Drug Deliv. Rev. 57, 411\u2013430 (2005).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"1185_CR15","unstructured":"ACIP Contraindications Guidelines for Immunization | CDC. https:\/\/www.cdc.gov\/vaccines\/hcp\/acip-recs\/general-recs\/contraindications.html (2024)."},{"key":"1185_CR16","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.addr.2014.10.002","volume":"93","author":"JL Tlaxca","year":"2015","unstructured":"Tlaxca, J. L., Ellis, S. & Remmele, R. L. Live attenuated and inactivated viral vaccine formulation and nasal delivery: potential and challenges. Adv. Drug Deliv. Rev. 93, 56\u201378 (2015).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"1185_CR17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.addr.2021.01.001","volume":"170","author":"J Pollet","year":"2021","unstructured":"Pollet, J., Chen, W.-H. & Strych, U. Recombinant protein vaccines, a proven approach against coronavirus pandemics. Adv. Drug Deliv. Rev. 170, 71\u201382 (2021).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"1185_CR18","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1089\/hum.2021.052","volume":"32","author":"A Bisgin","year":"2021","unstructured":"Bisgin, A., Sanlioglu, A. D., Eksi, Y. E., Griffith, T. S. & Sanlioglu, S. Current update on severe acute respiratory syndrome Coronavirus 2 vaccine development with a special emphasis on gene therapy viral vector design and construction for vaccination. Hum. Gene Ther. 32, 541\u2013562 (2021).","journal-title":"Hum. Gene Ther."},{"key":"1185_CR19","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa2202261","volume":"386","author":"L Dai","year":"2022","unstructured":"Dai, L. et al. Efficacy and safety of the RBD-Dimer-Based Covid-19 vaccine ZF2001 in adults. N. Engl. J. Med. 386, 2097\u20132111 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1185_CR20","doi-asserted-by":"publisher","unstructured":"Liang, J. et al. Nanoparticles in subunit vaccines: immunological foundations, categories, and applications. Small Weinh. Bergstr. Ger. e2407649 https:\/\/doi.org\/10.1002\/smll.202407649 (2024).","DOI":"10.1002\/smll.202407649"},{"key":"1185_CR21","doi-asserted-by":"publisher","first-page":"1152855","DOI":"10.3389\/fimmu.2023.1152855","volume":"14","author":"Y Gao","year":"2023","unstructured":"Gao, Y. & Guo, Y. Research progress in the development of natural-product-based mucosal vaccine adjuvants. Front. Immunol. 14, 1152855 (2023).","journal-title":"Front. Immunol."},{"key":"1185_CR22","doi-asserted-by":"publisher","first-page":"e2102435118","DOI":"10.1073\/pnas.2102435118","volume":"118","author":"E Kim","year":"2021","unstructured":"Kim, E. et al. Inhibition of elastase enhances the adjuvanticity of alum and promotes anti-SARS-CoV-2 systemic and mucosal immunity. Proc. Natl. Acad. Sci. USA118, e2102435118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1185_CR23","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/mi.2016.28","volume":"10","author":"D Christensen","year":"2017","unstructured":"Christensen, D., Mortensen, R., Rosenkrands, I., Dietrich, J. & Andersen, P. Vaccine-induced Th17 cells are established as resident memory cells in the lung and promote local IgA responses. Mucosal Immunol. 10, 260\u2013270 (2017).","journal-title":"Mucosal Immunol."},{"key":"1185_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4049\/jimmunol.1601775","volume":"199","author":"PN Boyaka","year":"2017","unstructured":"Boyaka, P. N. Inducing mMucosal IgA: a challenge for vaccine adjuvants and delivery systems. J. Immunol.199, 9\u201316 (2017).","journal-title":"J. Immunol."},{"key":"1185_CR25","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1002\/jps.22815","volume":"101","author":"MS Salnikova","year":"2012","unstructured":"Salnikova, M. S., Davis, H., Mensch, C., Celano, L. & Thiriot, D. S. Influence of formulation pH and suspension state on freezing-induced agglomeration of aluminum adjuvants. J. Pharm. Sci. 101, 1050\u20131062 (2012).","journal-title":"J. Pharm. Sci."},{"key":"1185_CR26","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.vaccine.2008.10.027","volume":"27","author":"LJ Braun","year":"2009","unstructured":"Braun, L. J. et al. Development of a freeze-stable formulation for vaccines containing aluminum salt adjuvants. Vaccine 27, 72\u201379 (2009).","journal-title":"Vaccine"},{"key":"1185_CR27","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.otc.2005.07.006","volume":"38","author":"BB Wrobel","year":"2005","unstructured":"Wrobel, B. B. & Leopold, D. A. Olfactory and sensory attributes of the nose. Otolaryngol. Clin. North Am. 38, 1163\u20131170 (2005).","journal-title":"Otolaryngol. Clin. North Am."},{"key":"1185_CR28","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1128\/CVI.00364-12","volume":"19","author":"MJ Darsley","year":"2012","unstructured":"Darsley, M. J. et al. The oral, live attenuated enterotoxigenic Escherichia coli vaccine ACE527 reduces the incidence and severity of diarrhea in a human challenge model of diarrheal disease. Clin. Vaccin. Immunol.19, 1921\u20131931 (2012).","journal-title":"Clin. Vaccin. Immunol."},{"key":"1185_CR29","doi-asserted-by":"publisher","first-page":"taad045","DOI":"10.1093\/jtm\/taad045","volume":"30","author":"A Kantele","year":"2023","unstructured":"Kantele, A. et al. Safety and immunogenicity of ETVAX\u00ae, an oral inactivated vaccine against enterotoxigenic Escherichia coli diarrhoea: a double-blinded, randomized, placebo-controlled trial amongst Finnish travellers to Benin, West Africa. J. Travel Med. 30, taad045 (2023).","journal-title":"J. Travel Med."},{"key":"1185_CR30","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1128\/mr.47.4.510-550.1983","volume":"47","author":"MM Levine","year":"1983","unstructured":"Levine, M. M., Kaper, J. B., Black, R. E. & Clements, M. L. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol. Rev. 47, 510\u2013550 (1983).","journal-title":"Microbiol. Rev."},{"key":"1185_CR31","first-page":"215","volume":"236","author":"LC Freytag","year":"1999","unstructured":"Freytag, L. C. & Clements, J. D. Bacterial toxins as mucosal adjuvants. Curr. Top. Microbiol. Immunol. 236, 215\u2013236 (1999).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"1185_CR32","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa030595","volume":"350","author":"M Mutsch","year":"2004","unstructured":"Mutsch, M. et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell\u2019s palsy in Switzerland. N. Engl. J. Med. 350, 896\u2013903 (2004).","journal-title":"N. Engl. J. Med."},{"key":"1185_CR33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-020-00451-w","volume":"6","author":"D Li","year":"2021","unstructured":"Li, D. & Wu, M. Pattern recognition receptors in health and diseases. Signal Transduct. Target. Ther. 6, 1\u201324 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1185_CR34","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/nrg2303","volume":"9","author":"F Leulier","year":"2008","unstructured":"Leulier, F. & Lemaitre, B. Toll-like receptors \u2014 taking an evolutionary approach. Nat. Rev. Genet. 9, 165\u2013178 (2008).","journal-title":"Nat. Rev. Genet."},{"key":"1185_CR35","doi-asserted-by":"crossref","unstructured":"Girkin, J. et al. TLR2-mediated innate immune priming boosts lung anti-viral immunity. Eur. Respir. J. 58, 1 2001584 (2021).","DOI":"10.1183\/13993003.01584-2020"},{"key":"1185_CR36","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1165\/rcmb.2005-0382OC","volume":"35","author":"IK Demedts","year":"2006","unstructured":"Demedts, I. K., Bracke, K. R., Maes, T., Joos, G. F. & Brusselle, G. G. Different roles for human lung dendritic cell subsets in pulmonary immune defense mechanisms. Am. J. Respir. Cell Mol. Biol. 35, 387\u2013393 (2006).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"1185_CR37","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1465-9921-11-2","volume":"11","author":"E Juarez","year":"2010","unstructured":"Juarez, E. et al. Differential expression of Toll-like receptors on human alveolar macrophages and autologous peripheral monocytes. Respir. Res. 11, 2 (2010).","journal-title":"Respir. Res."},{"key":"1185_CR38","doi-asserted-by":"publisher","first-page":"4037","DOI":"10.1039\/D2BM00061J","volume":"10","author":"D Ariawan","year":"2022","unstructured":"Ariawan, D., van Eersel, J., Martin, A. D., Ke, Y. D. & Ittner, L. M. Recent progress in synthetic self-adjuvanting vaccine development. Biomater. Sci. 10, 4037\u20134057 (2022).","journal-title":"Biomater. Sci."},{"key":"1185_CR39","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1021\/acs.jmedchem.0c01627","volume":"64","author":"A Kaur","year":"2021","unstructured":"Kaur, A. et al. TLR2 agonistic small molecules: detailed structure\u2013activity relationship, applications, and future prospects. J. Med. Chem. 64, 233\u2013278 (2021).","journal-title":"J. Med. Chem."},{"key":"1185_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34297-3","volume":"13","author":"AS Ashhurst","year":"2022","unstructured":"Ashhurst, A. S. et al. Mucosal TLR2-activating protein-based vaccination induces potent pulmonary immunity and protection against SARS-CoV-2 in mice. Nat. Commun. 13, 6972 (2022).","journal-title":"Nat. Commun."},{"key":"1185_CR41","doi-asserted-by":"crossref","unstructured":"Mv, S. et al. Protective efficacy of a mucosal influenza vaccine formulation based on the recombinant nucleoprotein Co-administered with a TLR2\/6 agonist BPPcysMPEG. Pharmaceutics 15, 912 (2023).","DOI":"10.3390\/pharmaceutics15030912"},{"key":"1185_CR42","doi-asserted-by":"publisher","first-page":"14440","DOI":"10.1021\/jacs.8b09223","volume":"140","author":"MD Morin","year":"2018","unstructured":"Morin, M. D. et al. Diprovocims: a new and exceptionally potent class of toll-like receptor agonists. J. Am. Chem. Soc. 140, 14440\u201314454 (2018).","journal-title":"J. Am. Chem. Soc."},{"key":"1185_CR43","first-page":"E8698","volume":"115","author":"Y Wang","year":"2018","unstructured":"Wang, Y. et al. Adjuvant effect of the novel TLR1\/TLR2 agonist Diprovocim synergizes with anti-PD-L1 to eliminate melanoma in mice. Proc. Natl. Acad. Sci. USA115, E8698\u2013E8706 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1185_CR44","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.actbio.2022.12.042","volume":"158","author":"H Chen","year":"2023","unstructured":"Chen, H. et al. Carrier-free subunit nanovaccine amplifies immune responses against tumors and viral infections. Acta Biomater. 158, 525\u2013534 (2023).","journal-title":"Acta Biomater."},{"key":"1185_CR45","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1093\/toxsci\/64.2.253","volume":"64","author":"JT Kelly","year":"2001","unstructured":"Kelly, J. T., Bobbitt, C. M. & Asgharian, B. In vivo measurement of fine and coarse aerosol deposition in the nasal airways of female long-evans rats. Toxicol. Sci. 64, 253\u2013258 (2001).","journal-title":"Toxicol. Sci."},{"key":"1185_CR46","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1080\/089583701300164249","volume":"13","author":"JT Kelly","year":"2001","unstructured":"Kelly, J. T., Kimbell, J. S. & Asgharian, B. Deposition of fine and coarse aerosols in a rat nasal mold. Inhal. Toxicol. 13, 577\u2013588 (2001).","journal-title":"Inhal. Toxicol."},{"key":"1185_CR47","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/jemt.1070230105","volume":"23","author":"EE Morrison","year":"1992","unstructured":"Morrison, E. E. & Costanzo, R. M. Morphology of olfactory epithelium in humans and other vertebrates. Microsc. Res. Tech. 23, 49\u201361 (1992).","journal-title":"Microsc. Res. Tech."},{"key":"1185_CR48","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1039\/C6NR07581A","volume":"9","author":"E Ahmad","year":"2017","unstructured":"Ahmad, E. et al. Evidence of nose-to-brain delivery of nanoemulsions: cargoes but not vehicles. Nanoscale 9, 1174\u20131183 (2017).","journal-title":"Nanoscale"},{"key":"1185_CR49","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.vaccine.2015.01.013","volume":"33","author":"L Zeng","year":"2015","unstructured":"Zeng, L. et al. Compound 48\/80 acts as a potent mucosal adjuvant for vaccination against Streptococcus pneumoniae infection in young mice. Vaccine 33, 1008\u20131016 (2015).","journal-title":"Vaccine"},{"key":"1185_CR50","doi-asserted-by":"crossref","unstructured":"Mao, L. et al. Novel synthetic lipopeptides as potential mucosal adjuvants enhanced SARS-CoV-2 rRBD-induced immune response. Front. Immunol. 13, 833418 (2022).","DOI":"10.3389\/fimmu.2022.833418"},{"key":"1185_CR51","doi-asserted-by":"publisher","first-page":"4037","DOI":"10.1172\/JCI60659","volume":"122","author":"J Helft","year":"2012","unstructured":"Helft, J. et al. Cross-presenting CD103+ dendritic cells are protected from influenza virus infection. J. Clin. Investig. 122, 4037\u20134047 (2012).","journal-title":"J. Clin. Investig."},{"key":"1185_CR52","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41577-020-00480-0","volume":"21","author":"L Dai","year":"2021","unstructured":"Dai, L. & Gao, G. F. Viral targets for vaccines against COVID-19. Nat. Rev. Immunol. 21, 73\u201382 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"1185_CR53","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41586-020-2548-6","volume":"584","author":"SJ Zost","year":"2020","unstructured":"Zost, S. J. et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature 584, 443\u2013449 (2020).","journal-title":"Nature"},{"key":"1185_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20501-9","volume":"12","author":"J Ge","year":"2021","unstructured":"Ge, J. et al. Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry. Nat. Commun. 12, 250 (2021).","journal-title":"Nat. Commun."},{"key":"1185_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-11816-2","volume":"12","author":"D Vimalajeewa","year":"2022","unstructured":"Vimalajeewa, D., Balasubramaniam, S., Berry, D. P. & Barry, G. Virus particle propagation and infectivity along the respiratory tract and a case study for SARS-CoV-2. Sci. Rep. 12, 7666 (2022).","journal-title":"Sci. Rep."},{"key":"1185_CR56","doi-asserted-by":"publisher","first-page":"103788","DOI":"10.1016\/j.ebiom.2021.103788","volume":"75","author":"L Azzi","year":"2022","unstructured":"Azzi, L. et al. Mucosal immune response in BNT162b2 COVID-19 vaccine recipients. eBioMedicine 75, 103788 (2022).","journal-title":"eBioMedicine"},{"key":"1185_CR57","doi-asserted-by":"publisher","first-page":"e68563","DOI":"10.7554\/eLife.68563","volume":"10","author":"S Khan","year":"2021","unstructured":"Khan, S. et al. SARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF-\u03baB pathway. eLife 10, e68563 (2021).","journal-title":"eLife"},{"key":"1185_CR58","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3109\/10611860108997935","volume":"9","author":"J Brooking","year":"2001","unstructured":"Brooking, J., Davis, S. S. & Illum, L. Transport of nanoparticles across the rat nasal mucosa. J. Drug Target. 9, 267\u2013279 (2001).","journal-title":"J. Drug Target."},{"key":"1185_CR59","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jconrel.2011.12.015","volume":"159","author":"J Kirch","year":"2012","unstructured":"Kirch, J. et al. Mucociliary clearance of micro- and nanoparticles is independent of size, shape and charge-an ex vivo and in silico approach. J. Control. Release159, 128\u2013134 (2012).","journal-title":"J. Control. Release"},{"key":"1185_CR60","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1084\/jem.20090410","volume":"206","author":"CH GeurtsvanKessel","year":"2009","unstructured":"GeurtsvanKessel, C. H. et al. Dendritic cells are crucial for maintenance of tertiary lymphoid structures in the lung of influenza virus-infected mice. J. Exp. Med. 206, 2339\u20132349 (2009).","journal-title":"J. Exp. Med."},{"key":"1185_CR61","doi-asserted-by":"publisher","first-page":"691","DOI":"10.3109\/08958378.2013.835889","volume":"25","author":"JD Schroeter","year":"2013","unstructured":"Schroeter, J. D., Asgharian, B., Price, O. T. & McClellan, G. E. Computational fluid dynamics simulations of inhaled nano- and microparticle deposition in the rhesus monkey nasal passages. Inhal. Toxicol. 25, 691\u2013701 (2013).","journal-title":"Inhal. Toxicol."},{"key":"1185_CR62","doi-asserted-by":"crossref","unstructured":"Ballesteros-Tato, A., Le\u00f3n, B., Lund, FE, & Randall, TD. Temporal changes in dendritic cell subsets, cross-priming and costimulation via CD70 control CD8(\u2009+\u2009) T cell responses to influenza. Nat. Immunol. 11, 216\u2013224 (2010).","DOI":"10.1038\/ni.1838"},{"key":"1185_CR63","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nrd2153","volume":"6","author":"JS Patton","year":"2007","unstructured":"Patton, J. S. & Byron, P. R. Inhaling medicines: delivering drugs to the body through the lungs. Nat. Rev. Drug Discov. 6, 67\u201374 (2007).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1185_CR64","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1038\/ni.1637","volume":"9","author":"RJ Snelgrove","year":"2008","unstructured":"Snelgrove, R. J. et al. A critical function for CD200 in lung immune homeostasis and the severity of influenza infection. Nat. Immunol. 9, 1074\u20131083 (2008).","journal-title":"Nat. Immunol."},{"key":"1185_CR65","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/s41578-023-00589-3","volume":"8","author":"J Kim","year":"2023","unstructured":"Kim, J. et al. In situ self-assembly for cancer therapy and imaging. Nat. Rev. Mater. 8, 710\u2013725 (2023).","journal-title":"Nat. Rev. Mater."},{"key":"1185_CR66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-022-01259-6","volume":"8","author":"F Cao","year":"2023","unstructured":"Cao, F. et al. Inside-out assembly of viral antigens for the enhanced vaccination. Signal Transduct. Target. Ther. 8, 1\u201314 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1185_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-022-01545-z","volume":"20","author":"Z Liao","year":"2022","unstructured":"Liao, Z. et al. Self-adjuvanting cancer nanovaccines. J. Nanobiotechnol. 20, 345 (2022).","journal-title":"J. Nanobiotechnol."},{"key":"1185_CR68","first-page":"443","volume":"18","author":"X Chen","year":"2019","unstructured":"Chen, X., Wang, T., Song, L. & Liu, X. Activation of multiple Toll-like receptors serves different roles in sepsis-induced acute lung injury. Exp. Ther. Med. 18, 443\u2013450 (2019).","journal-title":"Exp. Ther. Med."},{"key":"1185_CR69","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1007\/s12272-016-0806-9","volume":"39","author":"A Achek","year":"2016","unstructured":"Achek, A., Yesudhas, D. & Choi, S. Toll-like receptors: promising therapeutic targets for inflammatory diseases. Arch. Pharm. Res. 39, 1032\u20131049 (2016).","journal-title":"Arch. Pharm. Res."},{"key":"1185_CR70","doi-asserted-by":"publisher","first-page":"116773","DOI":"10.1016\/j.biopha.2024.116773","volume":"175","author":"J Zheng","year":"2024","unstructured":"Zheng, J., Li, Y., Kong, X. & Guo, J. Exploring immune-related pathogenesis in lung injury: providing new insights Into ALI\/ARDS. Biomed. Pharmacother. 175, 116773 (2024).","journal-title":"Biomed. Pharmacother."},{"key":"1185_CR71","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1073\/pnas.94.7.3256","volume":"94","author":"M Buschle","year":"1997","unstructured":"Buschle, M. et al. Transloading of tumor antigen-derived peptides into antigen-presenting cells. Proc. Natl. Acad. Sci. USA 94, 3256\u20133261 (1997).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1185_CR72","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.cell.2020.09.037","volume":"183","author":"L Piccoli","year":"2020","unstructured":"Piccoli, L. et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 Spike receptor-binding domain by structure-guided high-resolution serology. Cell 183, 1024\u20131042.e21 (2020).","journal-title":"Cell"},{"key":"1185_CR73","doi-asserted-by":"publisher","first-page":"eabd2223","DOI":"10.1126\/scitranslmed.abd2223","volume":"13","author":"D Sterlin","year":"2021","unstructured":"Sterlin, D. et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci. Transl. Med. 13, eabd2223 (2021).","journal-title":"Sci. Transl. Med."},{"key":"1185_CR74","unstructured":"Global Health Estimates: Life expectancy and leading causes of death and disability. https:\/\/www.who.int\/data\/gho\/data\/themes\/mortality-and-global-health-estimates."},{"key":"1185_CR75","unstructured":"Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect. Dis. 18, 1191\u20131210 (2018)."},{"key":"1185_CR76","doi-asserted-by":"publisher","first-page":"1005321","DOI":"10.3389\/fimmu.2022.1005321","volume":"13","author":"L Chen","year":"2022","unstructured":"Chen, L. et al. An intranasal vaccine targeting the receptor binding domain of SARS-CoV-2 elicits a protective immune response. Front. Immunol. 13, 1005321 (2022).","journal-title":"Front. Immunol."},{"key":"1185_CR77","doi-asserted-by":"publisher","first-page":"104545","DOI":"10.1016\/j.ebiom.2023.104545","volume":"90","author":"A Akerman","year":"2023","unstructured":"Akerman, A. et al. Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level. EBioMedicine 90, 104545 (2023).","journal-title":"EBioMedicine"},{"key":"1185_CR78","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-015-1263-7","volume":"15","author":"IJ Bakken","year":"2015","unstructured":"Bakken, I. J. et al. Febrile seizures after 2009 influenza A (H1N1) vaccination and infection: a nationwide registry-based study. BMC Infect. Dis. 15, 506 (2015).","journal-title":"BMC Infect. Dis."},{"key":"1185_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39096-y","volume":"14","author":"X Wang","year":"2023","unstructured":"Wang, X. et al. Vaccine-induced protection against SARS-CoV-2 requires IFN-\u03b3-driven cellular immune response. Nat. Commun. 14, 3440 (2023).","journal-title":"Nat. Commun."},{"key":"1185_CR80","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/j.1365-2567.2010.03288.x","volume":"130","author":"JR Lees","year":"2010","unstructured":"Lees, J. R. & Farber, D. L. Generation, persistence and plasticity of CD4 T-cell memories. Immunology 130, 463\u2013470 (2010).","journal-title":"Immunology"},{"key":"1185_CR81","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s13045-021-01205-z","volume":"14","author":"I Tsimafeyeu","year":"2021","unstructured":"Tsimafeyeu, I. et al. Safety and preliminary efficacy of the Gam-COVID-Vac vaccine and outcomes of SARS-CoV-2 infection in Russian patients with genitourinary malignancies. J. Hematol. Oncol.14, 192 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"1185_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00717-8","volume":"8","author":"C Singh","year":"2023","unstructured":"Singh, C. et al. Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin\u00ae). NPJ Vaccines 8, 125 (2023).","journal-title":"NPJ Vaccines"},{"key":"1185_CR83","doi-asserted-by":"publisher","first-page":"1239179","DOI":"10.3389\/fimmu.2023.1239179","volume":"14","author":"Z Zhang","year":"2023","unstructured":"Zhang, Z. et al. Boosting with an aerosolized Ad5-nCoV elicited robust immune responses in inactivated COVID-19 vaccines recipients. Front. Immunol. 14, 1239179 (2023).","journal-title":"Front. Immunol."},{"key":"1185_CR84","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3390\/vaccines11020455","volume":"11","author":"MS Dodaran","year":"2023","unstructured":"Dodaran, M. S. et al. Immunogenicity and safety of a combined intramuscular\/intranasal recombinant spike protein COVID-19 Vaccine (RCP) in healthy adults aged 18 to 55 years old: a randomized, double-blind, placebo-controlled, phase I Trial. Vaccines 11, 455 (2023).","journal-title":"Vaccines"},{"key":"1185_CR85","unstructured":"\u0421\u0430\u043b\u043d\u0430\u0432\u0430\u043a \u041a\u043e\u043c\u0431\u0438\u043d\u0438\u0440\u043e\u0432\u0430\u043d\u043d\u0430\u044f \u0432\u0435\u043a\u0442\u043e\u0440\u043d\u0430\u044f \u0432\u0430\u043a\u0446\u0438\u043d\u0430 \u0434\u043b\u044f \u043f\u0440\u043e\u0444\u0438\u043b\u0430\u043a\u0442\u0438\u043a\u0438 \u043a\u043e\u0440\u043e\u043d\u0430\u0432\u0438\u0440\u0443\u0441\u043d\u043e\u0439 \u0438\u043d\u0444\u0435\u043a\u0446\u0438\u0438, \u0432\u044b\u0437\u044b\u0432\u0430\u0435\u043c\u043e\u0439 \u0432\u0438\u0440\u0443\u0441\u043e\u043c SARS-CoV-2. medi.ru https:\/\/medi.ru\/instrukciya\/salnavak_27297\/."},{"key":"1185_CR86","unstructured":"\u0412\u043e\u0440\u043e\u043d\u0438\u043d\u0430, \u0415. \u041c\u0438\u043d\u0437\u0434\u0440\u0430\u0432 \u0437\u0430\u0440\u0435\u0433\u0438\u0441\u0442\u0440\u0438\u0440\u043e\u0432\u0430\u043b \u043d\u0430\u0437\u0430\u043b\u044c\u043d\u044b\u0439 \u00ab\u0421\u043f\u0443\u0442\u043d\u0438\u043a\u00bb. https:\/\/pharmvestnik.ru\/content\/news\/Minzdrav-zaregistriroval-nazalnyi-Sputnik.html (2022)."},{"key":"1185_CR87","doi-asserted-by":"publisher","first-page":"204ra130","DOI":"10.1126\/scitranslmed.3006516","volume":"5","author":"AV Li","year":"2013","unstructured":"Li, A. V. et al. Generation of effector memory T cell-based mucosal and systemic immunity with pulmonary nanoparticle vaccination. Sci. Transl. Med. 5, 204ra130 (2013).","journal-title":"Sci. Transl. Med."},{"key":"1185_CR88","doi-asserted-by":"publisher","unstructured":"Misharin, A. V., Morales-Nebreda, L., Mutlu, G. M., Budinger, G. R. S. & Perlman, H. Flow cytometric analysis of macrophages and dendritic cell subsets in the mouse lung. Am. J. Respir. Cell Mol. Biol. https:\/\/doi.org\/10.1165\/rcmb.2013-0086MA (2013).","DOI":"10.1165\/rcmb.2013-0086MA"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01185-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01185-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01185-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T13:03:25Z","timestamp":1750251805000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01185-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":88,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1185"],"URL":"https:\/\/doi.org\/10.1038\/s41541-025-01185-y","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,18]]},"assertion":[{"value":"29 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"127"}}